ArticlePloS one2012
Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 143 citations in OpenAlex.
- Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan.Clinical and vaccine immunology : CVI · 2013Trial
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- CD4+ T-cell immunity toDiscover immunity · 2026Review
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- Resurgence of pertussis: whopping the '100-day cough'.Current opinion in pediatrics · 2025Review
- Molecular epidemiology and genomic features of Bordetella pertussis in Tianjin, China, 2023.BMC microbiology · 2025Article
- Article
- Vaccine antigen-based genotyping ofMicrobiology spectrum · 2025Article
- [Analysis of the Pertussis Status in Jeju Special Self-Governing Province in 2024].Jugan geon-gang gwa jilbyeong · 2025Article
- Article
- Whole-genome comparison of two same-genotype macrolide-resistant Bordetella pertussis isolates collected in Japan.PloS one · 2024Article
- Genomic epidemiology and multilevel genome typing ofEmerging microbes & infections · 2023Article
- Vaccine Antigen Deficiency Does Not Substantially Affect the Identification of Bordetella pertussis Strains by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.Journal of clinical microbiology · 2023Article
- Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity.Vaccines · 2022Review
- Genotyping and macrolide-resistant mutation of Bordetella pertussis in East and South-East Asia.Journal of global antimicrobial resistance · 2022Article
- Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.Emerging infectious diseases · 2022Article
- Can vaccines control bacterial virulence and pathogenicity?Evolution, medicine, and public health · 2022Review
- Pathogenicity and virulence ofVirulence · 2021Review
- IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-FMucosal immunology · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adhesin pertactin (Prn) is one of the major virulence factors of Bordetella pertussis, the etiological agent of whooping cough. However, a significant prevalence of Prn-deficient (Prn(-)) B. pertussis was observed in Japan. The Prn(-) isolate was first discovered in 1997, and 33 (27%) Prn(-) isolates were identified among 121 B. pertussis isolates collected from 1990 to 2009. Sequence analysis revealed that all the Prn(-) isolates harbor exclusively the vaccine-type prn1 allele and that loss of Prn expression is caused by 2 different mutations: an 84-bp deletion of the prn signal sequence (prn1ΔSS, n = 24) and an IS481 insertion in prn1 (prn1::IS481, n = 9). The frequency of Prn(-) isolates, notably those harboring prn1ΔSS, significantly increased since the early 2000s, and Prn(-) isolates were subsequently found nationwide. Multilocus variable-number tandem repeat analysis (MLVA) revealed that 24 (73%) of 33 Prn(-) isolates belong to MLVA-186, and 6 and 3 Prn(-) isolates belong to MLVA-194 and MLVA-226, respectively. The 3 MLVA types are phylogenetically closely related, suggesting that the 2 Prn(-) clinical strains (harboring prn1ΔSS and prn1::IS481) have clonally expanded in Japan. Growth competition assays in vitro also demonstrated that Prn(-) isolates have a higher growth potential than the Prn(+) back-mutants from which they were derived. Our observations suggested that human host factors (genetic factors and immune status) that select for Prn(-) strains have arisen and that Prn expression is not essential for fitness under these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.